third sales currency were quarter currency translational of the a sales versus an the the of third increased X.X% sales as XXXX, negative OUS our effect had was outside reported In which was Thank regions U.S., U.S., by impact growth X.X of billion with excludes $XX.X Operational growth you, X.X% XXXX. sales outside increased increase growth, X.X quarter X.X% Joe. Worldwide X.X%. impacting U.S. of negatively reported points. X.X%. of for currency In the results Operational the points. our the
operational and X.X% growth U.S.; X.X% sales the Excluding worldwide; outside acquisitions of adjusted divestitures, the X.X% the was in net impact U.S. and
earnings, to were quarter and for $X.XX of per per diluted year was diluted earnings $X.X now Turning $X.XX billion net versus share the a share earnings earnings ago.
increases and adjusted periods, respectively adjusted grew to basis, per X.X%. Excluding earnings the after-tax X.X% was per operational third XXXX. earnings items the for diluted adjusted intangible and of share diluted share and net X.X% an $X.XX, for asset earnings $X.X On billion both special of amortization quarter compared representing quarter expense were
the on highlighting Beginning translation. Unless exclude of comparison otherwise impact you front segment operational quarter with the upon currency and will sales slides of in percentages of for build Health, Consumer stated, therefore the I change items the the quoted that you. in have quarter, performance to third XXXX, third now represent business sales comment
segment $X.X a sales Consumer billion totaled Worldwide X.X%. growing
X.X% acquisitions X.X% the our primarily divestitures, franchises. of with Growth operational growth beauty acquisition DR. franchise X% and outside strong to year-to-date digits U.S. in the in adjusted impact the beauty OTC all a across divestiture. of exclude impact was On was grew of net adjusted channel. ROC growth the grew X.X%. or the Consumer e-commerce and CI:LABO to the of and the in The sales Excluding performance basis, double U.S. due regions strong X.X% of
combined performance in the and and hair strong our the realized Share and sun protection due was with in cleansing, NEUTROGENA share categories product gains brands, relaunch. facial U.S. in growth promotions NEUTROGENA share results to line delivered treatment, due moisturizing the growth channel club AVEENO in of priority AVEENO to timing were Our
and ZARBEE’s share. growth Over-the-counter X% share operational release OTC the X.X% significant just over arthritis growing sales Adult X% which TYLENOL the over continues In and growth TYLENOL sales impact to products. to or the and drive by medicines adjusted growth contributor well. of exclude rapid was gel grew to is just adjusted core U.S., globally was acquisition when perform driven continues to the
ZYRTEC share. to grow market continued
supply However, relaunch of divestiture. retail X.X% decline disruption. U.S. the sales was baby the the declined care lapping Johnson's due declined associated most primarily This to with adjusted Concluding retail notably stocking XXXX or due in competitor Consumer segment, the due stocking BabyCenter exclude negative to impact X% globally to lapping baby to when the
Excluding comparisons, U.S. relaunch was flat. baby the
for X% the and our U.S. worldwide on and grew key U.S. segment, billion Moving products. by basis Generic pharmaceutical XXX double-digit competition increased grew outside in by our growth U.S. pharmaceutical the by to worldwide Sales ZYTIGA XXX X.X% points by and growth about sales in $XX.X enabled XX%. XX impacted respectively. negatively of
headwinds. at capabilities enabled levels above-market generic and commercial us strong growth Our deliver biosimilar global of has to and despite significant products portfolio
due to global XX% Our over Remicade STELARA, of SIMPONI of immunology by TREMFYA, Sales partially just to erosion portfolio discounts modest delivered action loss double-digit in strong alternative the continued and sales U.S. almost growth of performance and and driven growth share of by was XX% in SIMPONI biosimilars. in ARIA. mechanisms offset increased
market STELARA U.S. almost growth of compared has six XXXX. by XXXX. to is indication up about was the grew share the which the in the U.S., XX% of of achieved Crohn's share points points increased an in the third third from where primarily TREMFYA XX% over over disease X.X from X.X% and quarter the of market quarter psoriasis
Additionally, of arthritis. active approval of treatment FDA adults for the U.S. TREMFYA seeking application we filed with an psoriatic to
outside performance DARZALEX continued a quarter about about its and strong grew U.S. and adjusting market X.X from to share one-time continues in of globally benefit increase Our XX% of oncology across all the strong growth year delivered US worldwide the comparison about XX% adjustment The growth U.S. with XX% over reimbursement strong point of therapeutic impact therapy. the almost another to just area growing for favorable market X%. prior when lines or
the commercially available newly we continued in U.S. across where outside received driven well U.S. patients regimen The share growth region. the strong DARZALEX combination America as the the note, myeloma regulatory is Asia-Pacific and it penetration diagnosed with approval and EMEA eligible Latin increased for for XX transplant gains Of as multiple is countries by
data patient which total market X in above market strong across Latin of market markets. and gained market IMBRUVICA in outside share with indications line in lymphocytic leader CLL the and to patient therapy. and globally points driven and by of gained points all primarily of grew IMBRUVICA uptake second largely America U.S. the share approximately share the X.X the on the gains European, therapy along the be lines XX.X% share in Asia-Pacific, quarter based and U.S. strong new chronic leukemia growth U.S. continues In indication X.X in
castration-resistant XX% by prostate with Worldwide of XX% in generic growth continued almost market outside to almost progress pleased points due gained offset competition X declines share with XX% which partially about cancer, we U.S. U.S. growth continue ZYTIGA In be the which the the ERLEADA declined of of U.S. about non-metastatic the launch in by was of to strong
treatment with metastatic we quarter the cancer. during Joe As highlighted, approval the patients U.S. castration-sensitive of in the for prostate received
in We launch in are now countries. progress also is where available pleased ERLEADA with EMEA the X
patient long-acting persistency. by growing starts strong higher paliperidone portfolio well increased new with market share our Neuroscience XX% driven and performed In
In a the sites addition been Patient XXXX certified very over SPRAVATO. to and center need treatment is patients of we more actively and resistant are remains depression. XXX unmet of REMS treating program progress the SPRAVATO with demand high. strong treatment in To launch than have these become the date continue to
continued and treatment centers being We are patients. by encouraged progression of treating certified the
a for active who with the indication an reduction During the U.S. quarter depressive filed rapid in symptoms depressive second adults the have sNDA disorder intent. with we of ideation in major for suicidal
ill metabolism strong and and JULUCA for HIV In and our primarily X.X% partially diseases, X.X% grew other declines of competition medically XX% SYMTUZA with we were approval XARELTO product due pleased driven products. by of volume INVOKANA yesterday and along flat increases to sales treatment in an utilization. hole from offset PROCRIT. biosimilar did for rate just increase of other we with cardiovascular And donut to in rebates for the by donut by led offset XX% additional experience hole U.S. infectious competition and of generic for was XARELTO portfolio, VTE increased to indication higher declining population. the the legislative Medicare in In growth the portfolio cannibalization by primarily announce our in the for
both Our by with share. total impacted penetration the X.X% from entry by strong growing grew generic and TRACLEER, XX% pulmonary on a portfolio about in hypertension This benefited global and as the offset UPTRAVI outside growth as by negatively U.S. recent which Both OPSUMIT and well continued XX% basis. market generic performance increased respectively competition of was further was U.S. the in by
now your were Medical Devices segment. sales to I'll declining the turn X%. billion $X.X attention Medical Devices Worldwide
related points in of Excluding sales of items the by to the contributing in was Japan, basis net forward growth change LifeScan business. tax vision largely acquisitions divestitures about XX Growth the and primarily aided impacting consumption operational worldwide. adjusted the growth, one-time and of buying was ahead ASP, primarily quarter X.X% to impact divestitures,
majority the expect of XXXX. QX We QX sell-through remainder the in with this to occurring
catheters atrial led business, regions worldwide, over growth XX% newer our grew by achieving in growth. of market fibrillation growth. Solutions procedural XX% trend was about Interventional double-digit continuing to product and by electrophysiology in advanced ablation all continued Growth offerings in our globally, strong its driven strength contributing
antiarrhythmic less the During ablation as share trial XX to atrial were of treated years develop progression at catheter we drugs atrial were the the times fibrillation to likely than study initiation. ATTEST, standard patients quarter known after on three almost with pleased patients persistent which fibrillation results that showed
as delivered lenses of the grew OASYS quarter growth. driven well straight X.X% driven treatment including CERENOVUS in fifth market disposables by product new globally by of of X.X% strong led the a growth was business as contact family. growth daily by ischemic innovation EMBOTRAP which Vision our for Additionally, double-digit stroke
advance intraocular mentioned buy sales lens, launched vision of basis a I vision consumption increase globally. XXX total of our were intraocular aided continuous of by tax TECNIS lens. Japan earlier, points in forward a surgical As approximately in range vision In we Synergy a
the by reflects in our delivering quarterly continued Orthopedics growth execution significant position with primary and progress Hips in to continued X.X% commercial innovation approach, surgical the and our is the driven performance. growth improve quarter anterior continues the to stem system. our demand grew of strategies KINCISE improve acceleration ACTIS growth of XXXX. aimed automated for It largest strong since X.X%. leadership This the
basis was of U.S. the was in this line points rebate overall represent adoption by growth of leader the in to the driven and growth newer growth in item, almost Neck one-time reserve Femoral as with also adjustment or our innovation we performance by market such market. and are Adjusting market growth XX by globally. a trauma, as for X.X% expect globally our driving global growth Trauma Sales strong Nails. aided supported Recon System
decline. Spine declined with the X% being U.S. of less driver primary than the
surgery the such stabilization our PRIME EIT quarter. launched cellular newly System the invasive technology of CONDUIT driven Interbody to to minimally by titanium products printer as we degenerative new continue treat spine VIPER Platform disease, lost for we X-D in with share While and performance see
Knees in new S+. Revision and declines Cementless ATTUNE X.X% to market growth we select Revision uptake U.S. by ATTUNE represent quarter continues The led the by including in offset U.S. the positive other are U.S. innovation the growth and was around the of this ATTUNE market outside results strong in above XX.X% the to quarter OUS realize expected in U.S. double-digit the and from markets world. the performance launched with Knee system
to impact QX. show improvement all Pricing did pressure modest in to compared but orthopedics, continued categories
negative X% price U.S. approximately platforms was across X%. However, trauma, for Spine, and all with hips, knees all the declining declined about quarter. pure
that approximately results of X% in new of the driven in the to performance grew surgery region. all by Asia-Pacific Moving business, growth for strong in growth the share advanced global Surgery with gains X% primarily Biosurgery delivered to energy pleased being have over products by SURGIFLO led XXX X% and about of market July, were in regions, end the off impacting brought particularly We the one market points. the Asia-Pacific global of to by the with basis at region. in back the U.S. quarter, the month growth
purchases continued grew impacted closure gains share Timing by favorably barbed in almost sutures XXX Wound veterinary almost X% of in in growth market China. basis global and strong growth conventional driven the points. and by channel
us surgery, Additionally, we key in franchise. launched gastric, a powered stapler and first circular innovation general industry's the our thoracic for surgery colorectal, for
we global positive a growth As significant the third minor not impact expected, in selling days had do impact rates a expect in on and quarter our QX.
quarter. provide now will on commentary I some our earnings the for
Regarding please to our quarter the XXXX earnings for section statement boxed of third consolidated attention your the of direct of the schedule.
As the $X on billion earnings items quarter intangible intangible to by net third of exclude expense an special amortization of in and non-GAAP the primarily amortization asset adjusted table driven XXXX measures, after-tax billion. $X.X referenced of basis, are
X.X% Excluding XXXX. is $X.XX, third up items, versus increase the share was a third versus those impact constant adjusted the currency earnings of X.X% of our quarter per Adjusted EPS on $X.XX, XXXX. basis an quarter
the Pharmaceuticals quarter delevered quarter now leveraging Selling, and Pharmaceuticals of to result business. few administrative as the Devices for expense the Medical of Consumer as by improved driven currency impact that of the noteworthy segment well business. Cost and last slightly the mix, in compared to businesses, in a on margins earnings planned like marketing have changed products items as prioritization favorable the in a same primarily statement of sold highlight year. I'd negative
the by related invest Medical and This in higher We XXXX programs by higher development to key was third primarily a quarter in in XX our robotics, investment is sales and growth of basis continue our XX.X% digital to points. which levels percent Devices increase driven business investment was quarter as competitive platforms. and this research R&D at than
expense other lower lower The change due interest driven income line net was the effect balance. $XXX quarter interest of and was XXXX. recorded contingent debt in expense primarily the lower driven primarily a third arrangements and expense million hedging reversal in by of by to the by positive investment average liability Net
effective to XX.X%. the XXXX the of XX.X% in was our rate quarter quarter, rate taxes tax of compared Regarding third tax
impact XXXX the an favorable an the offset tax existing approximately the tax reserve The provisions includes adjustment impacting third a a effective X% for negatively tax rate. partially regarding reform. current financial estimated of recorded company to transition related quarter U.S. of Swiss tax by the As reminder, positions quarter reform of to benefit tax
encourage We this our to tax on and matters. reference you XX-Q further for other details specific
Excluding period by was adjustment same special XX.X% The year. increase items, rate driven previously tax to the the was in XX.X% the tax to noted. reserve positions compared effective last
a quarter the income increased XXXX to and tax. from for the in at looking in tax previously In percent enterprise noted. of Now for our XX.X% by margins adjusted XXXX primarily of as driven as quarter income improvements marketing administrative the third sales XX.X% before before adjusted selling,
drivers the XXX digital marketing main points selling of in by currency and due by was primarily to by optimization other adjusted by to sold. selling, segment. are marketing investment planned cost partially and investment basis R&D negative XXX offset decrease of Consumer points due margins points tax which items were and The following administrative solutions. income of of margins and income Medical by basis The before surgery basis the Pharmaceutical goods in expenses by in impact improved primarily robotics Devices optimization expenses. improved and driven XXX
concludes P&L third sales Johnson the That for and & highlights XXXX. Johnson's quarter
developments here comments. reference, in a summarizing quarter, occurring slide the in mentioned of some were is my notable third your For which
to will call Joe. I the back now turn
